RNA-seq Analysis Identified Hormone-related Genes Associated with Prognosis of Triple Negative Breast Cancer

Overview

Journal J Biomed Res

Specialty General Medicine

Date 2020 Apr 20

PMID 32305967

Citations 19

Authors

Fei Chen

Yuancheng Li

Na Qin

Fengliang Wang

Jiangbo Du

Cheng Wang

Fangzhi Du

Tao Jiang

Yue Jiang

Juncheng Dai

Zhibin Hu

Cheng Lu

Hongbing Shen

Affiliations

Soon will be listed here.

Abstract

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer that currently lacks effective biomarkers and therapeutic targets required to investigate the diagnosis and treatment of TNBC. Here we performed a comprehensive differential analysis of 165 TNBC samples by integrating RNA-seq data of breast tumor tissues and adjacent normal tissues from both our cohort and The Cancer Genome Atlas (TCGA). Pathway enrichment analysis was conducted to evaluate the biological function of TNBC-specific expressed genes. Further multivariate Cox proportional hazard regression was performed to evaluate the effect of these genes on TNBC prognosis. In this report, we identified a total of 148 TNBC-specific expressed genes that were primarily enriched in mammary gland morphogenesis and hormone levels related pathways, suggesting that mammary gland morphogenesis might play a unique role in TNBC patients differing from other breast cancer types. Further survival analysis revealed that nine genes ( , , , , , , , , and ) were significantly associated with the prognosis of TNBC patients, while three of them ( , , and ) were involved in the hormone-related pathways. These findings indicated the vital role of the hormone-related genes in TNBC tumorigenesis and may provide some independent prognostic markers as well as novel therapeutic targets for TNBC.

Citing Articles

HDAC10 inhibits non-small-cell lung cancer cell ferroptosis through the microRNA-223-5p-SLC7A11 axis.

Shi Z, Jiang T, Sun X, Peng L, Cao B, Wang Y Toxicol Res (Camb). 2024; 13(5):tfae164.

PMID: 39403124 PMC: 11471316. DOI: 10.1093/toxres/tfae164.

Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer.

Zhang W, Lee A, Tiwari A, Yang M Cells. 2024; 13(18.

PMID: 39329702 PMC: 11429566. DOI: 10.3390/cells13181518.

The analysis of transcriptomic signature of TNBC-searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity.

Supplitt S, Karpinski P, Sasiadek M, Laczmanski L, Kujawa D, Matkowski R J Appl Genet. 2024; 66(1):171-182.

PMID: 38722458 PMC: 11761126. DOI: 10.1007/s13353-024-00876-x.

Research insights into the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM): their roles in various tumors.

Duan S, Jiang Y, Li G, Fu W, Song Z, Li L PeerJ. 2024; 12:e16757.

PMID: 38223763 PMC: 10787544. DOI: 10.7717/peerj.16757.

The RNA m5C modification in R-loops as an off switch of Alt-NHEJ.

Yang H, Lachtara E, Ran X, Hopkins J, Patel P, Zhu X Nat Commun. 2023; 14(1):6114.

PMID: 37777505 PMC: 10542358. DOI: 10.1038/s41467-023-41790-w.

References

Bleach R, McIlroy M . The Divergent Function of Androgen Receptor in Breast Cancer; Analysis of Steroid Mediators and Tumor Intracrinology. Front Endocrinol (Lausanne). 2018; 9:594. PMC: 6213369. DOI: 10.3389/fendo.2018.00594. View

Chapman K, Prendes M, Kidd J, Sternberg H, West M, Wagner J . Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors. Biomark Med. 2013; 7(4):601-11. DOI: 10.2217/bmm.13.58. View

Shi Y, Zhao Y, Zhang Y, Aierken N, Shao N, Ye R . AFF3 upregulation mediates tamoxifen resistance in breast cancers. J Exp Clin Cancer Res. 2018; 37(1):254. PMC: 6192118. DOI: 10.1186/s13046-018-0928-7. View

Modugno F, Knoll C, Kanbour-Shakir A, Romkes M . A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2004; 82(3):191-7. DOI: 10.1023/B:BREA.0000004376.21491.44. View

Kwa M, Makris A, Esteva F . Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 2017; 14(10):595-610. DOI: 10.1038/nrclinonc.2017.74. View

Li H, Li J, Su Y, Fan Y, Guo X, Li L . A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth. Oncogene. 2013; 33(24):3109-18. DOI: 10.1038/onc.2013.282. View

Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson A . New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010; 42(2):105-16. PMC: 3018764. DOI: 10.1038/ng.520. View

Louie M, Sevigny M . Steroid hormone receptors as prognostic markers in breast cancer. Am J Cancer Res. 2017; 7(8):1617-1636. PMC: 5574935. View

Eswaran J, Cyanam D, Mudvari P, Reddy S, Pakala S, Nair S . Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep. 2012; 2:264. PMC: 3278922. DOI: 10.1038/srep00264. View

10.

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

11.

McNamara K, Oguro S, Omata F, Kikuchi K, Guestini F, Suzuki K . The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer. Breast Cancer Res Treat. 2016; 161(2):213-227. DOI: 10.1007/s10549-016-4050-2. View

12.

Xu G, Dang C . CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. Cancer Cell Int. 2017; 17:113. PMC: 5707824. DOI: 10.1186/s12935-017-0485-8. View

13.

Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S . American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16):2784-95. PMC: 2881855. DOI: 10.1200/JCO.2009.25.6529. View

14.

Pogoda K, Niwinska A, Murawska M, Pienkowski T . Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013; 30(1):388. PMC: 3586394. DOI: 10.1007/s12032-012-0388-4. View

15.

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

16.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

17.

Horvath A, Pakala S, Mudvari P, Reddy S, Ohshiro K, Casimiro S . Novel insights into breast cancer genetic variance through RNA sequencing. Sci Rep. 2013; 3:2256. PMC: 3722564. DOI: 10.1038/srep02256. View

18.

Weigelt B, Reis-Filho J . Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol. 2009; 6(12):718-30. DOI: 10.1038/nrclinonc.2009.166. View

19.

Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34. DOI: 10.1158/1078-0432.CCR-06-1109. View

20.

Bogdanov A, Moiseenko F, Dubina M . Abnormal expression of and in breast cancer. F1000Res. 2017; 6:10. PMC: 5428514. DOI: 10.12688/f1000research.10481.1. View